公开(公告)号：US20180216184A1

公开(公告)日：2018-08-02

申请号：US15752060

申请日：2016-09-22

Applicant: Epiontis GmbH

Inventor： Sven OLEK

IPC: C12Q1/6881

CPC classification number: C12Q1/6881 ,  C12Q2600/154

Abstract: The present invention relates to a method, in particular an in vitro method, for identifying monocytes, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for parkin RBR E3 ubiquitin protein ligase (PARK2), wherein a de-methylation or lack of methylation of said gene region is indicative for a monocyte, when compared to a non-monocyte cell. The analyses according to the invention can identify monocytes on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying monocytes, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Also claimed are kits and specific oligonucleotides for use as primers or probes.

公开(公告)号：US20180208985A1

公开(公告)日：2018-07-26

申请号：US15743402

申请日：2016-07-11

Applicant: NYU Winthrop Hospital

Inventor： Eitan Moshe Akirav

IPC: C12Q1/6883 ,  C12Q1/6858

CPC classification number: C12Q1/6883 ,  C12Q1/6858 ,  C12Q2600/154

Abstract: β-cell loss in In Type 1 diabetes is typically undetected until the development of hyperglycemia, at which point β-cell mass is significantly reduced. Methylation sensitive quantitative real time PCR (qRTPCR) of demethylated circulating free β-cell specific DNA can be used as a biomarker of β-cell death. Such DNA includes insulin gene and amylin gene DNA. Detection may be by determination of a gene demethylation index. Methylated and demethylated DNA may be distinguished by bisulfite treatment and use of specific PCR primers or probes to detect the different bisulfite treatment products. Detection of demethylated circulating free amylin DNA is useful in identifying β-cell death. The amylin DNA may be used in conjunction with other β-cell specific genes, such as insulin, to provide a multi-gene approach towards the detection of β-cell loss.

公开(公告)号：US20180195125A1

公开(公告)日：2018-07-12

申请号：US15784650

申请日：2017-10-16

Applicant: L2 Diagnostics, LLC

Inventor： Sahar Usmani-Brown

IPC: C12Q1/6883

CPC classification number: C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/16

Abstract: Described herein are compositions and methods for diagnosing or monitoring type 1 diabetes.

公开(公告)号：US10017824B2

公开(公告)日：2018-07-10

申请号：US14908695

申请日：2013-07-30

Applicant: BGI GENOMICS CO., LIMITED

Inventor： Xiaoyu Pan ,  Jing Guo ,  Hui Jiang ,  Fang Chen ,  Shengpei Chen ,  Shida Zhu ,  Fan Fan ,  Jialou Zhu

IPC: C12Q1/6853 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6851

CPC classification number: C12Q1/6886 ,  C12Q1/6827 ,  C12Q1/6851 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2523/125 ,  C12Q2531/113 ,  C12Q2537/143

Abstract: The present invention provides a method for determining the nucleic acid composition in a total nucleic acid mixture comprising a first nucleic acid and a second nucleic acid. The method comprises: 1) treating the total nucleic acid mixture with a bisulfate, to convert the non-methylated cytosine in the total nucleic acid mixture into uracil, and obtain a converted total nucleic acid mixture; 2) subjecting the converted total nucleic acid mixture to multiplexed fluorescent quantitative PCR using a first set of amplification primers and a second set of amplification primers; and 3) based on the ratio R of the methylated amplification product to the non-methylated amplification product of the predetermined nucleic acid fragment, a methylation proportion M1 of the predetermined nucleic acid fragment in the first nucleic acid, and a methylation proportion M2 of the predetermined nucleic acid fragment in the second nucleic acid, determining the nucleic acid composition in the total nucleic acid mixture.

公开(公告)号：US10017768B2

公开(公告)日：2018-07-10

申请号：US15153401

申请日：2016-05-12

Applicant: Wake Forest University Health Sciences

Inventor： Allen W. Tsang ,  Cristina M. Furdui

IPC: C07K16/28 ,  C07K16/32 ,  A61K31/517 ,  C12N15/113 ,  A61K31/5377 ,  A61K45/06 ,  C12Q1/6883 ,  G01N33/569 ,  A61K31/712 ,  C12Q1/689 ,  G01N33/68 ,  A61K39/00

CPC classification number: C12N15/1138 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/7088 ,  A61K31/712 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2320/31 ,  C12Q1/6883 ,  C12Q1/689 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/56927 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/485 ,  G01N2333/71 ,  G01N2800/26 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.

公开(公告)号：US20180187270A1

公开(公告)日：2018-07-05

申请号：US15899206

申请日：2018-02-19

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Hongzhi Zou ,  David A. Ahlquist

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal.

公开(公告)号：US10011878B2

公开(公告)日：2018-07-03

申请号：US14966938

申请日：2015-12-11

Applicant: EXACT SCIENCES DEVELOPMENT COMPANY, LLC ,  Mayo Foundation for Medical Education and Research

Inventor： David Alan Ahlquist ,  William Russell Taylor ,  Douglas W. Mahoney ,  Graham P. Lidgard ,  Hatim T. Allawi ,  Abram Michael Vaccaro

IPC: C07H21/04 ,  C12Q1/68 ,  C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/166

Abstract: Provided herein is technology relating to performing methylation assays. In particular, the technology relates to internal controls for methylation assays.

公开(公告)号：US09994911B2

公开(公告)日：2018-06-12

申请号：US14775435

申请日：2014-03-12

Applicant: Mayo Foundation for Medical Education and Research ,  EXACT SCIENCES DEVELOPMENT COMPANY, LLC

Inventor： David A. Ahlquist ,  John B. Kisiel ,  William R. Taylor ,  Tracy C. Yab ,  Douglas W. Mahoney ,  Graham P. Lidgard ,  Hatim T. Allawi

IPC: C07H21/04 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/154

Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer. Accordingly, provided herein is technology for pancreatic cancer screening markers and other gastrointestinal cancer screening markers that provide a high signal to-noise ratio and a low background level when detected from samples taken from a subject (e.g., stool sample). As described herein, the technology provides a number of methylated DNA markers and subsets thereof (e.g., sets of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more markers) with high discrimination for G1 neoplasms overall and/or at individual tumor sites.

公开(公告)号：US09994904B2

公开(公告)日：2018-06-12

申请号：US15011830

申请日：2016-02-01

Applicant: Robert Philibert ,  Anup Madan

Inventor： Robert Philibert ,  Anup Madan

IPC: C07H21/02 ,  G01N33/44 ,  C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q1/6869 ,  C12Q2600/112 ,  C12Q2600/124 ,  C12Q2600/154 ,  Y10T436/143333 ,  C12Q2523/125

Abstract: The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.

公开(公告)号：US09988683B2

公开(公告)日：2018-06-05

申请号：US12794449

申请日：2010-06-04

Applicant: Peter Adorjan ,  Matthias Burger ,  Sabine Maier ,  Ralf Lesche ,  Susan Cottrell ,  Suzanne Mooney

Inventor： Peter Adorjan ,  Matthias Burger ,  Sabine Maier ,  Ralf Lesche ,  Susan Cottrell ,  Suzanne Mooney

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/154 ,  Y10T436/143333

Abstract: Provided are methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Further provided are novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.